Cargando…

SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation

BACKGROUND: Smad interacting protein-1 is a transcription factor that is implicated in transforming growth factor-β/bone morphogenetic protein signaling and a repressor of E-cadherin and human telomerase reverse transcriptase. It is also involved in epithelial-mesenchymal transition and tumorigenesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Acun, Tolga, Oztas, Emin, Yagci, Tamer, Yakicier, Mustafa C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118200/
https://www.ncbi.nlm.nih.gov/pubmed/21645397
http://dx.doi.org/10.1186/1471-2407-11-223
_version_ 1782206435801694208
author Acun, Tolga
Oztas, Emin
Yagci, Tamer
Yakicier, Mustafa C
author_facet Acun, Tolga
Oztas, Emin
Yagci, Tamer
Yakicier, Mustafa C
author_sort Acun, Tolga
collection PubMed
description BACKGROUND: Smad interacting protein-1 is a transcription factor that is implicated in transforming growth factor-β/bone morphogenetic protein signaling and a repressor of E-cadherin and human telomerase reverse transcriptase. It is also involved in epithelial-mesenchymal transition and tumorigenesis. However, genetic and epigenetic alterations of SIP1 have not been fully elucidated in cancers. In this study, we investigated mutations and promoter hypermethylation of the SIP1 gene in human hepatocellular carcinomas. METHODS: SIP1 expression was analyzed in HCC cell lines and primary tumors in comparison to normal and non-tumor liver tissues by using semi-quantitative RT-PCR, quantitative real-time RT-PCR and immunohistochemistry. Mutation and deletion screening of the SIP1 gene were performed by direct sequencing in HCC-derived cells. Restoration of SIP1 expression was sought by treating HCC cell lines with the DNA methyl transferase inhibitor, 5-AzaC, and the histone deacetylase inhibitor, TSA. SIP1 promoter methylation was analyzed by the combined bisulfite restriction analysis assay in in silico-predicted putative promoter and CpG island regions. RESULTS: We found that the expression of SIP1 was completely lost or reduced in five of 14 (36%) HCC cell lines and 17 of 23 (74%) primary HCC tumors. Immunohistochemical analysis confirmed that SIP1 mRNA downregulation was associated with decreased expression of the SIP1 protein in HCC tissues (82.8%). No somatic mutation was observed in SIP1 exons in any of the 14 HCC cell lines. Combined treatment with DNA methyl transferase and histone deacetylase inhibitors synergistically restored SIP1 expression in SIP1-negative cell lines. Analysis of three putative gene regulatory regions revealed tumor-specific methylation in more than half of the HCC cases. CONCLUSIONS: Epigenetic mechanisms contribute significantly to the downregulation of SIP1 expression in HCC. This finding adds a new level of complexity to the role of SIP1 in hepatocarcinogenesis.
format Online
Article
Text
id pubmed-3118200
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31182002011-06-19 SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation Acun, Tolga Oztas, Emin Yagci, Tamer Yakicier, Mustafa C BMC Cancer Research Article BACKGROUND: Smad interacting protein-1 is a transcription factor that is implicated in transforming growth factor-β/bone morphogenetic protein signaling and a repressor of E-cadherin and human telomerase reverse transcriptase. It is also involved in epithelial-mesenchymal transition and tumorigenesis. However, genetic and epigenetic alterations of SIP1 have not been fully elucidated in cancers. In this study, we investigated mutations and promoter hypermethylation of the SIP1 gene in human hepatocellular carcinomas. METHODS: SIP1 expression was analyzed in HCC cell lines and primary tumors in comparison to normal and non-tumor liver tissues by using semi-quantitative RT-PCR, quantitative real-time RT-PCR and immunohistochemistry. Mutation and deletion screening of the SIP1 gene were performed by direct sequencing in HCC-derived cells. Restoration of SIP1 expression was sought by treating HCC cell lines with the DNA methyl transferase inhibitor, 5-AzaC, and the histone deacetylase inhibitor, TSA. SIP1 promoter methylation was analyzed by the combined bisulfite restriction analysis assay in in silico-predicted putative promoter and CpG island regions. RESULTS: We found that the expression of SIP1 was completely lost or reduced in five of 14 (36%) HCC cell lines and 17 of 23 (74%) primary HCC tumors. Immunohistochemical analysis confirmed that SIP1 mRNA downregulation was associated with decreased expression of the SIP1 protein in HCC tissues (82.8%). No somatic mutation was observed in SIP1 exons in any of the 14 HCC cell lines. Combined treatment with DNA methyl transferase and histone deacetylase inhibitors synergistically restored SIP1 expression in SIP1-negative cell lines. Analysis of three putative gene regulatory regions revealed tumor-specific methylation in more than half of the HCC cases. CONCLUSIONS: Epigenetic mechanisms contribute significantly to the downregulation of SIP1 expression in HCC. This finding adds a new level of complexity to the role of SIP1 in hepatocarcinogenesis. BioMed Central 2011-06-06 /pmc/articles/PMC3118200/ /pubmed/21645397 http://dx.doi.org/10.1186/1471-2407-11-223 Text en Copyright ©2011 Acun et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Acun, Tolga
Oztas, Emin
Yagci, Tamer
Yakicier, Mustafa C
SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
title SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
title_full SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
title_fullStr SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
title_full_unstemmed SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
title_short SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
title_sort sip1 is downregulated in hepatocellular carcinoma by promoter hypermethylation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118200/
https://www.ncbi.nlm.nih.gov/pubmed/21645397
http://dx.doi.org/10.1186/1471-2407-11-223
work_keys_str_mv AT acuntolga sip1isdownregulatedinhepatocellularcarcinomabypromoterhypermethylation
AT oztasemin sip1isdownregulatedinhepatocellularcarcinomabypromoterhypermethylation
AT yagcitamer sip1isdownregulatedinhepatocellularcarcinomabypromoterhypermethylation
AT yakiciermustafac sip1isdownregulatedinhepatocellularcarcinomabypromoterhypermethylation